Feasibility Study on the Use of Wireless Optogenetic Regulation of PD-L1 Expression to Remodel the Immune Microenvironment of Glioblastoma

Jiahe Su

doi:10.62177/apjcmr.v1i3.591

Authors

Jiahe Su Shanghai Shangde Experimental School

DOI:

https://doi.org/10.62177/apjcmr.v1i3.591

Keywords:

Wireless Optogenetics, Photosensitive System, PD-L1 Expression, Spatiotemporal Control, Tumor Suppression

Abstract

This study is based on wireless optogenetic technology, utilizing the CRY2/CIB1 photosensitive system to achieve spatiotemporal control of PD-L1 expression. In vitro experiments showed that the surface PD-L1 positivity rate of cells increased from 28.6±3.1% to 67.3±5.4% (P<0.001). In animal experiments, the terminal tumor volume in the light exposure group was 450±90 mm3, with a tumor inhibition rate of approximately 49.4% (P<0.001), and the median survival was extended to 32 days (compared to 24 days in the control group, P=0.004). Immunological tests revealed a significant increase in CD8+ T cell infiltration (112±18 vs 52±10 cells/HPF, P<0.01), a 30% decrease in the proportion of Tregs (P<0.05), and an increase in the M1/M2 macrophage ratio to 1.8. The results suggest that the wireless optogenetic system can not only precisely regulate PD-L1 but also remodel the tumor immune microenvironment, providing a new approach for precise immunotherapy of GBM.

Downloads

Download data is not yet available.

References

Makowska, M., Smolarz, B., & Romanowicz, H. (2023). MicroRNAs (miRNAs) in glioblastoma multiforme (GBM)—recent literature review. International Journal of Molecular Sciences, 24(4), 3521.

Tang, H., Wang, H., Fang, Y., Li, J., Zhang, L., Chen, K., ... & Li, Y. (2023). Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: A prospective multicenter randomized clinical trial. Annals of Oncology, 34(2), 163–172.

Lin, H., Liu, C., Hu, A., Li, L., Wang, X., Zhang, L., ... & Wang, Y. (2024). Understanding the immunosuppressive microenvironment of glioma: Mechanistic insights and clinical perspectives. Journal of Hematology & Oncology, 17(1), 31.

Armbruster, A., Mohamed, A. M. E., Phan, H. T., Gogolla, N., & Diester, I. (2024). Lighting the way: Recent developments and applications in molecular optogenetics. Current Opinion in Biotechnology, 87, 103126.

Bhardwaj, S., Sanjay, & Yadav, A. K. (2025). Higher isoform of hnRNPA1 confers temozolomide resistance in U87MG & LN229 glioma cells. Journal of Neuro-Oncology, 171(1), 47–63.